<DOC>
	<DOCNO>NCT00124748</DOCNO>
	<brief_summary>This study investigate safety efficacy 400mg Versus 800mg imatinib patient newly diagnose , previously untreated chronic myeloid leukemia chronic phase ( CML-CP ) use molecular endpoint .</brief_summary>
	<brief_title>Efficacy 400 Mg Versus 800 Mg Imatinib Chronic Myeloid Leukemia Chronic Phase Patients - TOPS ( Tyrosine Kinase Inhibitor Optimization Selectivity )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients within 6 month diagnosis ( date initial diagnosis date first cytogenetic analysis ) Diagnosis chronic myelogenous leukemia ( CML ) chronic phase cytogenetic confirmation Philadelphia chromosome ( 9 ; 22 ) translocation presence Breakpoint cluster region geneabelson protooncogene ( BcrAbl ) Documented chronic phase CML Adequate end organ function define : total bilirubin &lt; 1.5 x Upper Limit Normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) &lt; 2.5 x ULN creatinine &lt; 1.5 x ULN Patients late chronic phase , accelerated phase , blastic phase exclude Patients receive investigational agent Patients receive Gleevec/Glivec duration prior study entry , exception patient successfully complete [ CSTI571A2107 ( NCT00428909 ) ] study immediately prior participation study Patient receive treatment CML prior study entry longer 2 week exception hydroxyurea and/or anagrelide Patients another primary malignancy except primary malignancy neither currently clinically significant require active intervention Patients : ( ) pregnant , ( b ) breast feeding , ( c ) childbearing potential without negative pregnancy test prior baseline ( ) male female childbearing potential unwilling use barrier contraceptive precaution throughout trial ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Patient severe uncontrolled medical condition ( i.e. , uncontrolled diabetes , chronic renal disease ) Patient previously receive radiotherapy ≥ 25 % bone marrow Patient major surgery within 4 week prior study entry , recover prior major surgery Patients Eastern Cooperative Oncology Group ( ECOG ) Performance Status Score ≥ 3 Patients International normalized ratio ( INR ) partial thromboplastin time ( PTT ) &gt; 1.5 x ULN , exception patient treatment oral anticoagulant Patients know positivity human immunodeficiency virus ( HIV ) ; baseline test HIV require Patients identify sibling donor allogeneic bone marrow transplant elect first line treatment Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>CML</keyword>
	<keyword>Philadelphia positive</keyword>
	<keyword>Bcr-abl</keyword>
	<keyword>imatinib mesylate</keyword>
	<keyword>Chronic myeloid leukemia ( CML ) chronic phase</keyword>
</DOC>